At a glance
A combined research record involving tesamorelin and ipamorelin.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
This record brings together tesamorelin and ipamorelin. The scientific rationale draws on the component pathways, but a plausible combination is not proof of an additive or synergistic clinical effect. Identify the exact components, formulation and relative amounts before comparing it with a published study.[3][4][1]
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Tesamorelin + Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5mg + 5mg + 10mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL total)
| Week | Tesamorelin Dose | Ipamorelin Dose | Units (mL) |
|---|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 125 mcg (0.125 mg) | 23 units (0.23 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 250 mcg (0.25 mg) | 45 units (0.45 mL) |
| Weeks 5–6 | 1000 mcg (1.0 mg) | 500 mcg (0.5 mg) | 90 units (0.90 mL) |
| Weeks 7–10 | 1500 mcg (1.5 mg) | 750 mcg (0.75 mg) | 135 units (1.35 mL) |
| Weeks 11–16 | 2000 mcg (2.0 mg) | 1000 mcg (1.0 mg) | 180 units (1.80 mL) |
Route: Subcutaneous (SC) | Frequency: Once daily Note: The 1:1 blend ratio means tesamorelin and ipamorelin are present in equal amounts per mL. At 3.0 mL reconstitution: 1 mL = 1.67 mg tesamorelin + 1.67 mg ipamorelin. Higher‑volume injections (≥1.0 mL) may be split across two sites if preferred for comfort.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support pulsatile GH release through dual GHRH + ghrelin pathway stimulation[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks.
- Dose Range: Tesamorelin 250–2000 mcg + ipamorelin 125–1000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized refrigerated 2–8 °C; reconstituted use immediately or within 24–48 hours.
Suggested daily titration approach.
- Start: 250 mcg tesamorelin + 125 mcg ipamorelin daily; increase every 2 weeks.
- Target: 1500–2000 mcg tesamorelin + 750–1000 mcg ipamorelin by Weeks 7–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks.
- Timing: Evening or bedtime administration may align with natural GH secretion patterns[4]; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 24–48 hours[5].
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; may be kept at ≤25 °C (77 °F) up to 3 months after dispensing[5].
- Reconstituted: Inject immediately after reconstitution; if stored, refrigerate and use within 24–48 hours; do not freeze[5].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[6].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[6][9].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[6].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[5][10].
Materials & quantity planning
Source materials checklist · 5mg + 5mg + 10mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Tesamorelin 5 mg + Ipamorelin 5 mg, 10 mg blend each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 31 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (31 vials): 93 mL → 10 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
- 03
Public health resource
NCBI LiverTox — Tesamorelin — Synthetic GHRH analog; recommended dose 2 mg SC daily for HIV lipodystrophy (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Ipamorelin, the first selective growth hormone secretagogue — High GH potency and selectivity; no cortisol/ACTH effect (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Public health resource
FDA Egrifta (tesamorelin) Label — SC abdomen injection; rotate sites; storage and reconstitution guidance (opens in a new tab)www.accessdata.fda.gov
Back to overview ↑ - 07
Research publication
PubMed — Pharmacokinetic-pharmacodynamic modeling of ipamorelin — Human GH release peaked ~0.67 h post-dose (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
CDC — Vaccine Administration During — General subcutaneous route guidance (angle/site) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 10
Public health resource
NCBI Bookshelf — Best Practices for Injection — Asepsis, preparation, and administration guidance (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Research publication
PMC — Subcutaneous Drug Injection Review — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.